Alaunos Therapeutics, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On October 5, 2026, Alaunos Therapeutics received notice from its exchange regarding failure to satisfy continued listing standards, triggering Item 3.01 disclosure requirements. The filing provides no details on remediation timeline, specific non-compliance reasons, or appeal plans. This represents a critical regulatory threat to the company's public market status.
Why this rating
Delisting notice is existential threat to $9.6M market-cap company; loss of public listing status could destroy remaining equity value and access to capital markets. Highly material regardless of remediation possibility.
Extracted items
Price action (we called it negative)
before filing · preread $0.79 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.